Tailoring DNA vaccines: designing strategies against HER2 positive cancers
The crucial role of HER2 in epithelial transformation and its selective overexpression on cancer tissues makes it an ideal target for cancer immunotherapies such as passive immunotherapy with Trastuzumab. There are, however, a number of concerns regarding the use of monoclonal antibodies which inclu...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2013-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00122/full |
| _version_ | 1818693873375903744 |
|---|---|
| author | Cristina eMarchini Cristina eKalogris Chiara eGarulli lucia ePietrella Federico eGabrielli Claudia eCurcio Elena eQuaglino Federica eCavallo Augusto eAmici |
| author_facet | Cristina eMarchini Cristina eKalogris Chiara eGarulli lucia ePietrella Federico eGabrielli Claudia eCurcio Elena eQuaglino Federica eCavallo Augusto eAmici |
| author_sort | Cristina eMarchini |
| collection | DOAJ |
| description | The crucial role of HER2 in epithelial transformation and its selective overexpression on cancer tissues makes it an ideal target for cancer immunotherapies such as passive immunotherapy with Trastuzumab. There are, however, a number of concerns regarding the use of monoclonal antibodies which include resistance, repeated treatments, considerable costs and side effects that make active immunotherapies against HER2 desirable alternative approaches. The efficacy of anti-HER2 DNA vaccination has been widely demonstrated in transgenic cancer-prone mice, which recapitulate several features of human breast cancers. Nonetheless, the rational design of a cancer vaccine able to trigger a long lasting immunity, and thus prevent tumor recurrence in patients, would require the understanding of how tolerance and immunosuppression regulate antitumor immune responses and, at the same time, the identification of the most immunogenic portions of the target protein. We herein retrace the findings that led to our most promising DNA vaccines that, by encoding human/rat chimeric forms of HER2, are able to circumvent peripheral tolerance. Preclinical data obtained with these chimeric DNA vaccines have provided the rationale for their use in an ongoing phase I clinical trial (EudraCT 2011-001104-34). |
| first_indexed | 2024-12-17T13:20:36Z |
| format | Article |
| id | doaj.art-adc71bd4ee45471e90103da2b6f9e49a |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-17T13:20:36Z |
| publishDate | 2013-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-adc71bd4ee45471e90103da2b6f9e49a2022-12-21T21:46:53ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2013-05-01310.3389/fonc.2013.0012248048Tailoring DNA vaccines: designing strategies against HER2 positive cancersCristina eMarchini0Cristina eKalogris1Chiara eGarulli2lucia ePietrella3Federico eGabrielli4Claudia eCurcio5Elena eQuaglino6Federica eCavallo7Augusto eAmici8University of CamerinoUniversity of CamerinoUniversity of CamerinoUniversity of CamerinoUniversity of CamerinoUniversity of ChietiUniversity of TurinUniversity of TurinUniversity of CamerinoThe crucial role of HER2 in epithelial transformation and its selective overexpression on cancer tissues makes it an ideal target for cancer immunotherapies such as passive immunotherapy with Trastuzumab. There are, however, a number of concerns regarding the use of monoclonal antibodies which include resistance, repeated treatments, considerable costs and side effects that make active immunotherapies against HER2 desirable alternative approaches. The efficacy of anti-HER2 DNA vaccination has been widely demonstrated in transgenic cancer-prone mice, which recapitulate several features of human breast cancers. Nonetheless, the rational design of a cancer vaccine able to trigger a long lasting immunity, and thus prevent tumor recurrence in patients, would require the understanding of how tolerance and immunosuppression regulate antitumor immune responses and, at the same time, the identification of the most immunogenic portions of the target protein. We herein retrace the findings that led to our most promising DNA vaccines that, by encoding human/rat chimeric forms of HER2, are able to circumvent peripheral tolerance. Preclinical data obtained with these chimeric DNA vaccines have provided the rationale for their use in an ongoing phase I clinical trial (EudraCT 2011-001104-34).http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00122/fullImmunotherapybreast cancerHER2immunological toleranceDNA Vaccines |
| spellingShingle | Cristina eMarchini Cristina eKalogris Chiara eGarulli lucia ePietrella Federico eGabrielli Claudia eCurcio Elena eQuaglino Federica eCavallo Augusto eAmici Tailoring DNA vaccines: designing strategies against HER2 positive cancers Frontiers in Oncology Immunotherapy breast cancer HER2 immunological tolerance DNA Vaccines |
| title | Tailoring DNA vaccines: designing strategies against HER2 positive cancers |
| title_full | Tailoring DNA vaccines: designing strategies against HER2 positive cancers |
| title_fullStr | Tailoring DNA vaccines: designing strategies against HER2 positive cancers |
| title_full_unstemmed | Tailoring DNA vaccines: designing strategies against HER2 positive cancers |
| title_short | Tailoring DNA vaccines: designing strategies against HER2 positive cancers |
| title_sort | tailoring dna vaccines designing strategies against her2 positive cancers |
| topic | Immunotherapy breast cancer HER2 immunological tolerance DNA Vaccines |
| url | http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00122/full |
| work_keys_str_mv | AT cristinaemarchini tailoringdnavaccinesdesigningstrategiesagainsther2positivecancers AT cristinaekalogris tailoringdnavaccinesdesigningstrategiesagainsther2positivecancers AT chiaraegarulli tailoringdnavaccinesdesigningstrategiesagainsther2positivecancers AT luciaepietrella tailoringdnavaccinesdesigningstrategiesagainsther2positivecancers AT federicoegabrielli tailoringdnavaccinesdesigningstrategiesagainsther2positivecancers AT claudiaecurcio tailoringdnavaccinesdesigningstrategiesagainsther2positivecancers AT elenaequaglino tailoringdnavaccinesdesigningstrategiesagainsther2positivecancers AT federicaecavallo tailoringdnavaccinesdesigningstrategiesagainsther2positivecancers AT augustoeamici tailoringdnavaccinesdesigningstrategiesagainsther2positivecancers |